Abeona Therapeutics (ABEO) Operating Income (2011 - 2026)

Abeona Therapeutics' Operating Income history runs 16 years deep, the most recent figure standing at -$23.0 million for Q1 2026.

• In Q1 2026, Operating Income fell 16.76% year-over-year to -$23.0 million; the TTM figure through Mar 2026 stood at $11.7 million (up 116.76% YoY), while the FY2025 annual figure was $15.0 million, up 123.31% from the prior year.
• Operating Income was -$23.0 million for Q1 2026 at Abeona Therapeutics, down from $81.5 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $81.5 million in Q4 2025 to a low of -$24.0 million in Q3 2025.
• Historically, Operating Income has averaged -$10.0 million across 5 years, with a median of -$14.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Operating Income tumbled 69.26% in 2024, then soared 588.89% in 2025.
• A 5-year view of Operating Income shows it stood at -$12.9 million in 2022, then declined by 2.11% to -$13.2 million in 2023, then declined by 26.22% to -$16.7 million in 2024, then jumped by 588.89% to $81.5 million in 2025, then tumbled by 128.26% to -$23.0 million in 2026.
• The last three Operating Income figures came in at -$23.0 million (Q1 2026), $81.5 million (Q4 2025), and -$24.0 million (Q3 2025), per Business Quant data.